In a murine model of multiple myeloma, the combined blockade using POM-1, AZD4635, and an anti-CD73 antibody significantly enhances the activation of immune cells, increases IFN-γ levels, and reduces tumor burden [320]. This evidence concerns the gene NT5E and plasma cell myeloma.